RxDoctor Payments Data

Lawrence Cox, DO

Family Medicine · Lewisberry, PANPI 1871559393

Payments from drug & device makers

$19,018in general payments, 2019–2025

Across 1,485 payments — averaging $12.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$3K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • Pfizer$940
  • plus $7K from 46 others

What the payments were for

  • Food & beverage$18,971100%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,018 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$217,516
Medicare patients
440
Services billed
3,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin233$218,676
OzempicSemaglutide128$185,330
EliquisApixaban95$111,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$75,141
MounjaroTirzepatide44$67,976
XareltoRivaroxaban31$48,752
JanuviaSitagliptin Phosphate33$41,134
TrulicityDulaglutide30$37,383
FarxigaDapagliflozin Propanediol43$32,872
Tresiba Flextouch U-100Insulin Degludec33$27,388
RybelsusSemaglutide31$26,596
ProliaDenosumab15$25,464
JentaduetoLinagliptin/Metformin Hcl13$15,511
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$14,730
Atorvastatin Calcium699$11,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto$1,195$234,187246 claims
Novo NordiskOzempic, Rybelsus$3,483$211,926159 claims
PfizerEliquis$940$111,63995 claims
Lilly USA, LLCMounjaro, Trulicity$1,102$105,35974 claims
GSKTrelegy Ellipta, Anoro Ellipta$2,092$89,871105 claims
Johnson & JohnsonXarelto$623$48,75231 claims
MerckJanuvia$447$41,13433 claims
AstraZenecaFarxiga$651$32,87243 claims
AmgenProlia$600$25,46415 claims
AbbVieSynthroid$3,260$3,24258 claims
Sanofi-aventis U.S. LLCLantus$49$3,10516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Lewisberry

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →